Therapeutics Update: Important New Drugs and Their Mortality Implications
This webinar was featured live June 1 and 2, 2022. Please register to view the recording.
Register
The FDA approved 50 new drugs in 2021. Many of these are of great interest to life and health insurers, including precisely targeted biologic cancer agents, neuropsychiatric medications, drugs that treat or help prevent HIV, and treatments for COVID-19.
In this one-hour webinar, we’ll review several of these new therapeutics and their mortality implications. We’ll show you how these drugs appear in real-time Prescription Data and Medical Data, and how Irix® instantly interprets their use and relative mortality to give you the most up-to-date picture of an applicant’s health, so you can underwrite with confidence.
Topics covered
- Increasing drug complexity: Using Medical Data to spot intravenous cancer agents that don’t show up in prescription histories
- New drugs for both the care and prevention of HIV that have widely varying implications for mortality
- Oral and injectable treatments for COVID-19
- Using updated Prescription Data with Medical Data to stratify risks for patients with serious conditions like diabetes or heart failure
Who should attend
Medical directors, underwriters, and other clinical professionals working in the insurance industry will benefit from a review of significant new drug therapies—and a refresher on the insurtech that helps carriers see both risks and opportunities, to quickly make the best-informed decisions.
Presenter
Kyle Schimeck, PharmD, BcPS
Clinical Consultant
